Covance Inc (CVD) 96.97 $CVD
In Vitro Toxicity Testing to Grow at a 15.84% CAGR to 2018 Says a New Research Report at ReportsnReports.com
PRWeb - Mon Apr 14, 2:58AM CDT
Cosmetic as well as chemical companies are trying to market and sell their products by campaigning animal-free testing. Popular brands of cosmetics are implementing animal-free testing policies to market and sell their products. Vendors are targeting compassionate consumers by marketing their products as Cruelty-free food Cosmetics And clothing as cruelty-free testing does not damage the environment or produce harmful waste. Analysts forecast the Global In Vitro Toxicity Testing market will grow at a CAGR of 15.84 percent over the period 2013-2018. According to the report, the Global In Vitro Toxicity Testing market is driven by several factors, of which an increase in opposition to animal testing is one of the major drivers. Since animals are used as test subjects, toxicity testing is opposed by the majority of animal rights activists. This results in the increased adoption of in vitro toxicity testing and helps in the growth of the market. Covered in this Report The Global In Vitro Toxicity Testing market can be divided into four end-user segments: Cosmetics and Personal Care Industry, Pharmaceuticals Industry, Food Industry, and Chemicals Industry. The Global In Vitro Toxicity Testing Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the market. In addition, the report discusses the major drivers that influence the growth of the Global In Vitro Toxicity Testing market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The report also includes a discussion of the key vendors operating in this market. Key Regions Americas EMEA APAC Key Vendors Accelrys Inc. Bio-Rad Laboratories Inc. Charles River Laboratories International Inc. Covance Inc. Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=280671. Other Prominent Vendors Entelos Inc. Mattek Corp. Molecular Toxicology Inc. RTI Health Solutions SBW Ltd. Smithers Group Inc. Xenobiotic Detection Systems Inc. Xenometrix AG Key Market Driver Increasing Opposition to Animal Testing. Key Market Challenge Concerns about Accuracy and Reliability of the Test. Key Market Trend Increase in Animal-free Testing Campaigns. Further, the report states that the accuracy and reliability of in vitro toxicity testing is one of the major challenges faced by the market vendors. In vitro toxicity testing requires proper laboratory setup as well as high-quality cell and tissue culture and good aseptic techniques. The report recognizes the following companies as the key players in Global In-vitro Toxicity Testing Market: Accelrys Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc. , Covance Inc. , Entelos Inc., MattekCorp., Molecular Toxicology Inc., RTI Health Solutions, SBW Ltd., Smithers Group Inc., Xenobiotic Detection SystemsInc., Xenometrix AG. Key Questions Answered in this Report What will the market size be in 2018 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro
Healthcare Companies Report Recognitions, Schedules, and Stock Movements - Analyst Notes on WellPoint, Quest Diagnostics, LabCorp, Covance, and Masimo
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Quest Diagnostics Inc. (NYSE: DGX), Laboratory Corp. of America Holdings (NYSE: LH), Covance Inc. (NYSE: CVD), and Masimo Corporation (NASDAQ: MASI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Interesting CVD Put And Call Options For November 22nd
DividendChannel.com - Mon Apr 07, 10:21AM CDT
Investors in Covance Inc. saw new options become available this week, for the November 22nd expiration.
Covance Shares Up 12.5% Since SmarTrend's Buy Recommendation (CVD)
Comtex SmarTrend(R) - Mon Apr 07, 9:22AM CDT
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 4 months, Covance has returned 12.46% as of today's recent price of $98.35.
Covance Inc. Invites You to Join the Webcast of Its First Quarter 2014 Financial Results Conference Call
PR Newswire - Thu Apr 03, 9:55AM CDT
In conjunction with its first quarter 2014 earnings release (expected to be issued after market close on May 1, 2014), Covance Inc. (NYSE: CVD) is pleased to invite you to listen to its quarterly investor conference call that will be broadcast live over the Internet on Friday, May 2, 2014 at 9:00 a.m. ET.
Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts
M2 - Tue Apr 01, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnnrlm/healthcare_bpo) has announced the addition of the "Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts" report to their offering. The global healthcare BPO market is dominated by the U.S. A very large percentage of the healthcare BPO requirement arises out of the U.S. Europe is quickly emerging as another important source segment in this market. The U.S. and India are the two largest destination geographies. Philippines and Eastern Europe are two of the fastest growing destination segments in this market. The payer market is segmented into claims processing, member services, HR services, and finance and accounts segments. Claims processing is an important service segment in the payer outsourcing market. It is further sub-divided into claims indexing, claims investigation, claims adjudication, claims repricing, claims settlement, litigation management, and information management. The provider market is segmented into medical billing, medical coding, medical transcription, and finance and account segments. The pharmaceutical outsourcing market is segmented into contract research organizations (CRO), contract manufacturing organizations (CMO), and business support services. Each service segment in the pharmaceutical outsourcing market is divided into further sub-segments. The CRO service segment is sub-divided into drug discovery, pre-clinical, clinical phases I, II, III and IV, clinical data management and biostatistics, medical writing, regulatory services, and non-clinical functions. The CMO service segment is sub-divided into API manufacturing, and formulation and packaging. The non-clinical service segment is sub-divided into supply chain management and logistics, sales and marketing, and non-clinical functions. The report also highlights the marketing KPO function in the sales and marketing outsourcing segment. Scope Healthcare BPO Market Payer - Claims Processing - HR Services - Finance & Accounts Provider - Medical Billing & Coding Pharmaceutical - Clinical Trial - Contract Manufacturing - Non-Clinical Services Key Topics Covered: - Introduction - Executive Summary - Market Overview - Healthcare Payer Outsourcing Market - Healthcare Provider Outsourcing Market - Pharmaceutical Outsourcing Market - Geographical Analysis - Competitive Landscape - Company Profiles - Accenture Plc - Accretive Health, Inc. - Anthelio Healthcare Solutions, Inc. - Boehringer Ingelheim Gmbh - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. - Cognizant Technology Solutions Corporation - Covance, Inc. - Gebbs Healthcare Solutions, Inc. - Genpact Limited - Ibm Corporation - Icon Plc - Igate Patni - Infosys Bpo Limited - Inventiv Health Inc - Lonza Group Ltd. - Medusind Solutions Inc - Mphasis Limited - Omega Healthcare Management Services Pvt Ltd - Parexel International Corporation - Patheon Inc - Pharmaceutical Product Development, Inc. - Piramal Enterprises Limited - Quintiles Transnational Holdings, Inc. - Tata Consultancy Services Ltd - Tech Mahindra - Teleradiology Solutions Pvt Ltd. - Wns (Holdings) Limited - Xerox Corporation Visit http://www.researchandmarkets.com/research/hn...thcare_bpo
4 Disruptive Stocks Biotechs Depend On
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 5:30PM CDT
It's easy for investors to fall into the trap of chasing markets higher and lower, especially when the media machine hypes booms and busts. However, investors that chase market pops and drops rarely come out ahead in the long haul. Instead,...
16.0% Return Seen to Date on SmarTrend Covance Call (CVD)
Comtex SmarTrend(R) - Fri Mar 28, 5:01PM CDT
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 4 months, Covance has returned 16.01% as of today's recent price of $101.45.
Healthcare Companies Make Presentations, Submissions, Investigation Extensions, and Expansions - Analyst Notes on CR Bard, Medivation, Align Technology, Covance, and PAREXEL
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CR Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and PAREXEL International Corporation (NASDAQ: PRXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Covance Up 19.0% Since SmarTrend Uptrend Call (CVD)
Comtex SmarTrend(R) - Fri Mar 21, 11:09AM CDT
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 3 months, Covance has returned 19.03% as of today's recent price of $104.09.
Covance Crafts New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 9:30AM CDT
On March 20, 2014, shares of Covance reached a new 52-week high of $105.88.
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned
M2 - Wed Mar 12, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmb6vx/mice_model_market) has announced the addition of the "Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. Over the years, the use of mice models has increased rapidly. Mice have become the animals of choice for preclinical research in academic institutions as well as in pharmaceutical and biotechnology industries. The market has seen many innovations in the last few years, as companies have introduced new models for studying diseases like cancer and AIDS. This report categorizes the market into two broad segments, namely, mice models and services. By type, the market comprises of inbred, outbred, knockout, conditioned/surgically modified, hybrid/congenic, and spontaneous mutant mice. The inbred mice segment holds the largest share of 58% of the mice model market in 2013. This high share of inbred mice is attributed to their ability to reproduce the same results in different laboratories over a period of time. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The breeding services market holds the largest share of the services market and is expected to grow at the highest CAGR of 15% from 2013 to 2018, to reach $521 million by 2018. The mice care products market is categorized into cages, bedding, feed, and others. The caging market accounts for the largest share of the mice care products market, growing at a CAGR of 2.8% from 2013 to 2018 to reach $67.1 million in 2018. High investments and grants, which are leading to rising innovations in mice models, is a key factor that is likely to drive the growth of this market. In addition, the increase in the number of R&D activities in pharmaceutical industries, which are the prime users of mice models, is also responsible for driving this market. Furthermore, the high genetic similarity between mice and humans is another factor that is driving the use of mice models, globally. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/lm...del_market
Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019
M2 - Mon Mar 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh67xx/life_sciences_bpo) has announced the addition of the "Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019" report to their offering. The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies. Pharmaceutical companies are now forming long term partnership with the CROs and CMOs to share the costs involved in drug discovery to post marketing approvals. Moreover, they are also leveraging CROs and CMOs expertise such as use of novel technologies, trained staff and previous experiences for effective outcomes. The research report on life sciences BPO provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of life sciences BPO on the basis of different CRO and CMO services. The CRO services comprises clinical data management, monitoring, medical writing, regulatory services, pharmacovigilance, bio-statistics, drug discovery and pre-clinical tests. The CMO services include API manufacturing, Finished Dosage Formulation development and manufacturing and Packaging. The global life sciences BPO market has been segmented based on all the above- mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in terms of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global life sciences BPO market.The section also covers opportunities, market attractiveness analysis and Porter's Five Forces analysis for the market participants. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Life Sciences BPO Market Dynamics Chapter 4 Global Life Sciences BPO Market, by Segments Chapter 5 Global Life Sciences BPO Market, by Geography Chapter 6 Global Life Sciences BPO Market Share Analysis Chapter 7 Recommendations Chapter 8 Company Profiles - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/gh...iences_bpo
Coverage on Covance Initiated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:20PM CST
On Mar 06, 2014, we initiated coverage on Covance.
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
In Vitro Toxicity Testing to Grow at a 15.84% CAGR to 2018 Says a New Research Report at ReportsnReports.com
PRWeb - Mon Apr 14, 2:58AM CDT
Cosmetic as well as chemical companies are trying to market and sell their products by campaigning animal-free testing. Popular brands of cosmetics are implementing animal-free testing policies to market and sell their products. Vendors are targeting compassionate consumers by marketing their products as Cruelty-free food Cosmetics And clothing as cruelty-free testing does not damage the environment or produce harmful waste. Analysts forecast the Global In Vitro Toxicity Testing market will grow at a CAGR of 15.84 percent over the period 2013-2018. According to the report, the Global In Vitro Toxicity Testing market is driven by several factors, of which an increase in opposition to animal testing is one of the major drivers. Since animals are used as test subjects, toxicity testing is opposed by the majority of animal rights activists. This results in the increased adoption of in vitro toxicity testing and helps in the growth of the market. Covered in this Report The Global In Vitro Toxicity Testing market can be divided into four end-user segments: Cosmetics and Personal Care Industry, Pharmaceuticals Industry, Food Industry, and Chemicals Industry. The Global In Vitro Toxicity Testing Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the market. In addition, the report discusses the major drivers that influence the growth of the Global In Vitro Toxicity Testing market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The report also includes a discussion of the key vendors operating in this market. Key Regions Americas EMEA APAC Key Vendors Accelrys Inc. Bio-Rad Laboratories Inc. Charles River Laboratories International Inc. Covance Inc. Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=280671. Other Prominent Vendors Entelos Inc. Mattek Corp. Molecular Toxicology Inc. RTI Health Solutions SBW Ltd. Smithers Group Inc. Xenobiotic Detection Systems Inc. Xenometrix AG Key Market Driver Increasing Opposition to Animal Testing. Key Market Challenge Concerns about Accuracy and Reliability of the Test. Key Market Trend Increase in Animal-free Testing Campaigns. Further, the report states that the accuracy and reliability of in vitro toxicity testing is one of the major challenges faced by the market vendors. In vitro toxicity testing requires proper laboratory setup as well as high-quality cell and tissue culture and good aseptic techniques. The report recognizes the following companies as the key players in Global In-vitro Toxicity Testing Market: Accelrys Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc. , Covance Inc. , Entelos Inc., MattekCorp., Molecular Toxicology Inc., RTI Health Solutions, SBW Ltd., Smithers Group Inc., Xenobiotic Detection SystemsInc., Xenometrix AG. Key Questions Answered in this Report What will the market size be in 2018 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro
Healthcare Companies Report Recognitions, Schedules, and Stock Movements - Analyst Notes on WellPoint, Quest Diagnostics, LabCorp, Covance, and Masimo
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Quest Diagnostics Inc. (NYSE: DGX), Laboratory Corp. of America Holdings (NYSE: LH), Covance Inc. (NYSE: CVD), and Masimo Corporation (NASDAQ: MASI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Interesting CVD Put And Call Options For November 22nd
DividendChannel.com - Mon Apr 07, 10:21AM CDT
Investors in Covance Inc. saw new options become available this week, for the November 22nd expiration.
Covance Shares Up 12.5% Since SmarTrend's Buy Recommendation (CVD)
Comtex SmarTrend(R) - Mon Apr 07, 9:22AM CDT
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 4 months, Covance has returned 12.46% as of today's recent price of $98.35.
Covance Inc. Invites You to Join the Webcast of Its First Quarter 2014 Financial Results Conference Call
PR Newswire - Thu Apr 03, 9:55AM CDT
In conjunction with its first quarter 2014 earnings release (expected to be issued after market close on May 1, 2014), Covance Inc. (NYSE: CVD) is pleased to invite you to listen to its quarterly investor conference call that will be broadcast live over the Internet on Friday, May 2, 2014 at 9:00 a.m. ET.
Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts
M2 - Tue Apr 01, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnnrlm/healthcare_bpo) has announced the addition of the "Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts" report to their offering. The global healthcare BPO market is dominated by the U.S. A very large percentage of the healthcare BPO requirement arises out of the U.S. Europe is quickly emerging as another important source segment in this market. The U.S. and India are the two largest destination geographies. Philippines and Eastern Europe are two of the fastest growing destination segments in this market. The payer market is segmented into claims processing, member services, HR services, and finance and accounts segments. Claims processing is an important service segment in the payer outsourcing market. It is further sub-divided into claims indexing, claims investigation, claims adjudication, claims repricing, claims settlement, litigation management, and information management. The provider market is segmented into medical billing, medical coding, medical transcription, and finance and account segments. The pharmaceutical outsourcing market is segmented into contract research organizations (CRO), contract manufacturing organizations (CMO), and business support services. Each service segment in the pharmaceutical outsourcing market is divided into further sub-segments. The CRO service segment is sub-divided into drug discovery, pre-clinical, clinical phases I, II, III and IV, clinical data management and biostatistics, medical writing, regulatory services, and non-clinical functions. The CMO service segment is sub-divided into API manufacturing, and formulation and packaging. The non-clinical service segment is sub-divided into supply chain management and logistics, sales and marketing, and non-clinical functions. The report also highlights the marketing KPO function in the sales and marketing outsourcing segment. Scope Healthcare BPO Market Payer - Claims Processing - HR Services - Finance & Accounts Provider - Medical Billing & Coding Pharmaceutical - Clinical Trial - Contract Manufacturing - Non-Clinical Services Key Topics Covered: - Introduction - Executive Summary - Market Overview - Healthcare Payer Outsourcing Market - Healthcare Provider Outsourcing Market - Pharmaceutical Outsourcing Market - Geographical Analysis - Competitive Landscape - Company Profiles - Accenture Plc - Accretive Health, Inc. - Anthelio Healthcare Solutions, Inc. - Boehringer Ingelheim Gmbh - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. - Cognizant Technology Solutions Corporation - Covance, Inc. - Gebbs Healthcare Solutions, Inc. - Genpact Limited - Ibm Corporation - Icon Plc - Igate Patni - Infosys Bpo Limited - Inventiv Health Inc - Lonza Group Ltd. - Medusind Solutions Inc - Mphasis Limited - Omega Healthcare Management Services Pvt Ltd - Parexel International Corporation - Patheon Inc - Pharmaceutical Product Development, Inc. - Piramal Enterprises Limited - Quintiles Transnational Holdings, Inc. - Tata Consultancy Services Ltd - Tech Mahindra - Teleradiology Solutions Pvt Ltd. - Wns (Holdings) Limited - Xerox Corporation Visit http://www.researchandmarkets.com/research/hn...thcare_bpo
4 Disruptive Stocks Biotechs Depend On
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 5:30PM CDT
It's easy for investors to fall into the trap of chasing markets higher and lower, especially when the media machine hypes booms and busts. However, investors that chase market pops and drops rarely come out ahead in the long haul. Instead,...
16.0% Return Seen to Date on SmarTrend Covance Call (CVD)
Comtex SmarTrend(R) - Fri Mar 28, 5:01PM CDT
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 4 months, Covance has returned 16.01% as of today's recent price of $101.45.
Healthcare Companies Make Presentations, Submissions, Investigation Extensions, and Expansions - Analyst Notes on CR Bard, Medivation, Align Technology, Covance, and PAREXEL
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CR Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and PAREXEL International Corporation (NASDAQ: PRXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Covance Up 19.0% Since SmarTrend Uptrend Call (CVD)
Comtex SmarTrend(R) - Fri Mar 21, 11:09AM CDT
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on December 9th, 2013 at $87.45. In approximately 3 months, Covance has returned 19.03% as of today's recent price of $104.09.
Covance Crafts New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 9:30AM CDT
On March 20, 2014, shares of Covance reached a new 52-week high of $105.88.
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned
M2 - Wed Mar 12, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmb6vx/mice_model_market) has announced the addition of the "Mice Model Market 2014 - Forecasts to 2018: Inbred, Knockout & Conditioned" report to their offering. The global market (models and services) is valued at $1,115.2 million in 2013 and is expected to reach $1,819.9 million by 2018, growing at a CAGR of 10.3% from 2013 to 2018. Over the years, the use of mice models has increased rapidly. Mice have become the animals of choice for preclinical research in academic institutions as well as in pharmaceutical and biotechnology industries. The market has seen many innovations in the last few years, as companies have introduced new models for studying diseases like cancer and AIDS. This report categorizes the market into two broad segments, namely, mice models and services. By type, the market comprises of inbred, outbred, knockout, conditioned/surgically modified, hybrid/congenic, and spontaneous mutant mice. The inbred mice segment holds the largest share of 58% of the mice model market in 2013. This high share of inbred mice is attributed to their ability to reproduce the same results in different laboratories over a period of time. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and other services (surgical and line rescue). The breeding services market holds the largest share of the services market and is expected to grow at the highest CAGR of 15% from 2013 to 2018, to reach $521 million by 2018. The mice care products market is categorized into cages, bedding, feed, and others. The caging market accounts for the largest share of the mice care products market, growing at a CAGR of 2.8% from 2013 to 2018 to reach $67.1 million in 2018. High investments and grants, which are leading to rising innovations in mice models, is a key factor that is likely to drive the growth of this market. In addition, the increase in the number of R&D activities in pharmaceutical industries, which are the prime users of mice models, is also responsible for driving this market. Furthermore, the high genetic similarity between mice and humans is another factor that is driving the use of mice models, globally. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Market Share Analysis, By Key Players 5 Mice Model Market Size 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles 9 Preclinical Pipeline 10 Industry Speaks 11 Cost Assessment and Mouse Model Outlicensing/Buyer Companies Assessment Companies Mentioned - Ablexis, LLC - Charles River Laboratories, Inc. - Covance, Inc. - Crescendo Biologics, - Deltagen, Inc. - Genoway Sa - Harbour Antibodies Bv - Harlan Laboratories, Inc. - Immunogenes Ag - Ingenious Targeting Laboratory - Lexicon Pharmaceuticals, Inc. - Mirimus, Inc. - Sage Labs - Taconic Farms, Inc. - The Jackson Laboratory - Transgenic, Inc. For more information visit http://www.researchandmarkets.com/research/lm...del_market
Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019
M2 - Mon Mar 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh67xx/life_sciences_bpo) has announced the addition of the "Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019" report to their offering. The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies. Pharmaceutical companies are now forming long term partnership with the CROs and CMOs to share the costs involved in drug discovery to post marketing approvals. Moreover, they are also leveraging CROs and CMOs expertise such as use of novel technologies, trained staff and previous experiences for effective outcomes. The research report on life sciences BPO provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of life sciences BPO on the basis of different CRO and CMO services. The CRO services comprises clinical data management, monitoring, medical writing, regulatory services, pharmacovigilance, bio-statistics, drug discovery and pre-clinical tests. The CMO services include API manufacturing, Finished Dosage Formulation development and manufacturing and Packaging. The global life sciences BPO market has been segmented based on all the above- mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in terms of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global life sciences BPO market.The section also covers opportunities, market attractiveness analysis and Porter's Five Forces analysis for the market participants. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Life Sciences BPO Market Dynamics Chapter 4 Global Life Sciences BPO Market, by Segments Chapter 5 Global Life Sciences BPO Market, by Geography Chapter 6 Global Life Sciences BPO Market Share Analysis Chapter 7 Recommendations Chapter 8 Company Profiles - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/gh...iences_bpo
Coverage on Covance Initiated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:20PM CST
On Mar 06, 2014, we initiated coverage on Covance.
Favorable Court Judgments, Stock Price Updates, and Upcoming Investors Conferences - Analyst Notes on Salix, Cerner, Hologic, Covance, and Synta
PR Newswire - Thu Mar 06, 8:20AM CST
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
